Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature
- Conditions
- Primary Vascular Dysregulation
- Interventions
- Registration Number
- NCT01201551
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
It is already known that the local treatment with Alphagan eye drops (a drug commonly used by glaucoma patients) reduces ocular blood flow. In-vitro studies suggest that the vasoconstrictive effect of Alphagan is more pronounced when this drug is combined with a prostaglandin analogue (eg. Xalatan eye drops). The investigators also question whether this effect is more pronounced in subjects suffering from a primary vascular dysregulation (PVD). To test for the effect of these drugs on PVD and non-PVD subjects the investigators will take measurements of corneal temperature as surrogate for ocular blood flow.
- Detailed Description
The investigators would like to investigate the effect of Alphagan eye drops, Xalatan eye drops and their combination (both Alphagan and Xalatan) on corneal temperature in healthy subjects with and without a primary vascular dysregulation (PVD).
The investigators would like to answer the following questions:
1. Do the individual drugs influence the circulation to the eye as quantified indirectly via corneal temperature?
2. Does the combination of Alphagan and Xalatan give an additive or even potentiated effect?
3. Is the sequence of application of drugs of relevance (Alphagan applied first, Xalatan second, or vice versa)?
4. Do PVD and non-PVD subjects respond differently to these drugs?
20 healthy non-PVD subjects and 20 healthy PVD subjects in the age range from 20-40 years will be recruited. Recruited subjects will have all measurements: corneal temperature, intraocular pressure (IOP), ear temperature, blood-pressure. Both prior to and after instillation of eye drops (Xalatan, Alphagan and placebo).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- healthy
- age 18-48 years
- normal findings on ophthalmological examination
- history of ocular or systemic disease
- chronic or current systemic or topical medication
- drug or alcohol abuse
- art. hypertension
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description healthy subjects without PVD Placebo healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo healthy subjects with PVD Placebo healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo healthy subjects with PVD Latanoprost healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo healthy subjects without PVD Brimonidine healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo healthy subjects without PVD Latanoprost healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo healthy subjects with PVD Brimonidine healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
- Primary Outcome Measures
Name Time Method Corneal temperature Week 1: day 1 and 2 before eyedrops and after. Week 2: day 1 and 2 before eyedrops and after.
- Secondary Outcome Measures
Name Time Method Blood pressure Week 1: day 1 and 2 before eyedrops and after. Week 2: day 1 and 2 before eyedrops and after. Intraocular pressure Week 1: day 1 and 2 before eyedrops and after. Week 2: day 1 and 2 before eyedrops and after. Ear temperature Week 1: day 1 and 2 before eyedrops and after. Week 2: day 1 and 2 before eyedrops and after.
Trial Locations
- Locations (1)
University of Basel, Dept. of Ophthalmology
🇨ðŸ‡Basel, Switzerland